Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients
Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients
复制标题
乙型肝炎抗体在预测白血病患者已治愈的乙型肝炎病毒感染再激活中的作用
DOI：
10.1016/j.antiviral.2020.104765
复制
发表时间：
2020
影响因子：
7.6
通讯作者：
Pan Xiao-Ben
中科院分区：
文献类型：
--
作者：
Wu Tian;Wu Nan;Ma Yan-Xiu;Wu Jing;Gao Yan;Pan Xiao-Ben
背景与目的定量检测抗-HBs和抗-HBc可预测接受利妥昔单抗治疗的淋巴瘤患者发生HBV再激活（HBV r）的风险。然而，目前还不清楚是否定量是预测HBVr白血病患者接受immunosuppress.Methodsand患者：临床和实验室数据的白血病患者之间的解决HBV感染诊断2013年1月至2018年3月进行了回顾性收集。资料系列的HBV血清标志物和HBV DNA水平的患者接受化疗和/或造血干细胞移植（HSCT）和在随访期间进行了分析during.ResultsIn总数，533例白血病患者解决HBV感染。HSCT组和化疗组HBVr检出率分别为5.7%（25/441）和2.2%（2/92）。HSCT患者中，急性淋巴细胞白血病患者HBV r阳性率明显高于急性髓细胞白血病患者（8.9%vs3.9%，P < 0.05）。由于HBV抗体谱的差异，发病率几乎为零至40%。基线时高抗-HBs（临界值为79.2 IU/L）或低抗-HBc水平（临界值为4.475，S/CO）与HBV r低风险相关。抗-HBe状态对HBV感染率无影响。然而，截止值仅预测HBVr的患者谁有阴性抗-HBe.ConclusionThe基线配置文件的HBV抗体进行免疫抑制的白血病患者HBVr的风险是预测。然而，血清阴性抗-HBe是使用基线抗-HBs和抗-HBc定量预测HBV风险的先决条件。
Background & AimsQuantification of anti-HBs and anti-HBc predicts the risk of HBV reactivation (HBVr) in lymphoma patients receiving rituximab treatment. However, it remains unclear whether the quantification is predictive of HBVr in leukemia patients undergoing immunosuppression.Methodsand patients: Clinical and laboratory data of the leukemia patients with resolved HBV infection diagnosed between January 2013 and March 2018 were retrospectively collected. Data series of HBV seromarkers and HBV DNA levels before the patients receiving chemotherapy and/or hematopoietic stem cell transplantation (HSCT) and during follow-up duration were analyzed.ResultsIn total, 533 leukemia patients with resolved HBV infection were included. The incidences of HBVr were 5.7% (25/441) and 2.2% (2/92) in patients receiving HSCT and chemotherapy, respectively. In patients receiving HSCT, acute lymphoid leukemia had a significantly higher incidence of HBVr than acute myeloid leukemia (8.9%vs3.9%,P< 0.05). The incidence varied almost zero to 40% due to the differences in the profiles of HBV antibodies. High anti-HBs (cut-off of 79.2 IU/L) or low anti-HBc levels (cut-off of 4.475, S/CO) at baseline were associated with a low risk of HBVr. Anti-HBe status did not affect the incidence of HBVr. However, the cut-offs were only predictive of HBVr in the patients who had negative anti-HBe.ConclusionThe baseline profiles of HBV antibodies are predictive of the risk of HBVr in leukemia patients undergoing immunosuppression. However, seronegative anti-HBe is a prerequisite for using baseline anti-HBs and anti-HBc quantification to predict HBVr risk.